# Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

> **NCT00460603** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 187 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** AG-013726
- **DRUG:** AG-013736 (axitinib)

## Key facts

- **NCT ID:** NCT00460603
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-11
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2013-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460603, "Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00460603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*